Participant flow

Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients · Source last updated 2017-09-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Velcade: Single dose of Velcade (1.0-1.3 mg/m2 dose)

   id

   FG000

   title

   All Participants

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Withdrawal by Subject

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         8

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         7

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice